2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.44 Short-course Immunotherapy Prior to Targeted Therapy in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: A Retrospective Study

EP.12A.44 Short-course Immunotherapy Prior to Targeted Therapy in EGFR-Mutated Metastatic Non-Small Cell Lung Cancer: A Retrospective Study

Back to course

Pdf Summary

The study, led by Peiling Chen at The First Affiliated Hospital of Guangzhou Medical University, investigates the efficacy and safety of a short course of immunotherapy (IO) prior to targeted therapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant (EGFRm) non-small cell lung cancer (NSCLC). Conducted as a retrospective analysis, the study examined EGFRm metastatic non-small cell lung cancer (mNSCLC) patients treated between June 17, 2019, and June 17, 2023. <br /><br />Patients received 1-4 cycles of first-line immunotherapy combined with chemotherapy and anti-angiogenesis therapy before transitioning to EGFR tyrosine kinase inhibitor (TKI) therapy upon mutation confirmation. The study encompassed 22 patients with an average age of 59.27 years. Most had adenocarcinoma (86.36%), with 36.36% being female. The mutations identified were exon 19 deletions in thirteen patients and L858R mutation in nine patients.<br /><br />The treatment strategy achieved an objective response rate (ORR) of 77.27% overall, and 44.44% in the subset evaluated after the IO course. Remarkably, the disease control rate (DCR) was 100%. Adverse events of grade 3 (9.09% of patients) included hepatic dysfunction and myelosuppression, which were manageable. Median progression-free survival (PFS) was estimated at approximately 879.125 days (95% CI: 638.139-1120.111).<br /><br />The study highlights that initiating immunotherapy before targeted therapy is feasible, manageable in terms of safety, and potentially effective. The findings suggest the need for further research with larger patient cohorts and extended follow-up to understand the long-term impact of early immunotherapy on subsequent EGFR-targeted treatments, thereby contributing to personalized treatment strategies for EGFR-mutated mNSCLC.

Asset Subtitle

Peiling Chen

Meta Tag

Speaker Peiling Chen

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

immunotherapy

targeted therapy

EGFR-mutant

non-small cell lung cancer

NSCLC

retrospective analysis

EGFR tyrosine kinase inhibitor

objective response rate

disease control rate

progression-free survival